Abstract

Objective: Mycoplasma
pneumoniae (MP) remains an important cause of respiratory tract infections and community-acquired pneumonia in children and has regained prominence in the post–COVID-19 period. We aimed to evaluate pediatricians’ knowledge of pediatric MP infection across key clinical domains and to compare knowledge according to professional experience.

Materials and Methods: This single-center, cross-sectional, questionnaire-based study was conducted in November–December 2025. A literature-based, face-to-face survey with 29 multiple-choice items (single best answer) assessed knowledge in four domains: risk factors (5 items), clinical manifestations/complications (8 items), diagnostic tests (6 items), and treatment (10 items). Participants were stratified by experience (0–5 years vs. ≥6 years). Item-level correct response rates were compared using chi-square/Fisher’s exact tests, and domain scores were compared using the Mann–Whitney U test.

Results: A total of 126 physicians participated (0–5 years: n=93; ≥6 years: n=33). Domain-level knowledge scores were comparable between groups across risk factors, clinical manifestations/complications, diagnostic tests, and treatment. However, several item-level differences were observed; these item-level comparisons were exploratory. Physicians with ≥6 years of experience more frequently answered correctly questions related to the incubation period, cutaneous manifestations, limitations of serologic testing, and identification of an antibiotic ineffective against M.pneumoniae infection. In contrast, physicians with 0–5 years of experience more frequently answered correctly items concerning post-infection immunity, the most commonly affected age group, M.pneumoniae-associated CNS disease, hospitalization-related knowledge, and management of MP-associated hemolytic anemia.

Conclusion: Overall knowledge of pediatric M.pneumoniae infection was comparable across experience strata at the domain level; however, item-level findings should be interpreted cautiously as exploratory. These findings support an institution-wide, high-yield educational package prioritizing diagnostic test interpretation (particularly serology), recognition of extrapulmonary manifestations, and evidence-based antimicrobial selection in the post–COVID-19 period.

References

  1. Hu J, Ye Y, Chen X, Xiong L, Xie W, Liu P. Insight into the Pathogenic Mechanism of Mycoplasma pneumoniae. Curr Microbiol. 2023;80(1):14. https://doi.org/10.1007/s00284-022-03103-0
  2. Gao L, Sun Y. Laboratory diagnosis and treatment of Mycoplasma pneumoniae infection in children: a review. Ann Med. 2024; 56(1):2386636. https://doi.org/10.1080/07853890.2024.2386636
  3. Sharplin L, Goyal V. Mycoplasma pneumoniae respiratory tract infections in children: when and how to diagnose and treat. Breathe (Sheff). 2025;21(4):250046. https://doi.org/10.1183/20734735.0046-2025
  4. Tsai TA, Tsai CK, Kuo KC, Yu HR. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. Journal of Microbiology, Immunology and Infection. 2021;54(4):557-65. https://doi.org/10.1016/j.jmii.2020.10.002
  5. Edens C, Clopper BR, DeVies J, Benitez A, McKeever ER, Johns D, et al. Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018-2024. MMWR Morb Mortal Wkly Rep. 2024;73(7):149-51. https://doi.org/10.15585/mmwr.mm7307a3
  6. Ding L, Jiang Y. Biomarkers associated with the diagnosis and prognosis of Mycoplasma pneumoniae pneumonia in children: a review. Front Cell Infect Microbiol. 2025;15: 1552144. https://doi.org/10.3389/fcimb.2025.1552144
  7. Li X, Li T, Chen N, Kang P, Yang J. Changes of Mycoplasma pneumoniae prevalence in children before and after COVID-19 pandemic in Henan, China. Journal of Infection. 2023;86(3):256-308. https://doi.org/10.1016/j.jinf.2022.12.030
  8. Diaz MH, Hersh AL, Olson J, Shah SS, Hall M, Edens C. Mycoplasma pneumoniae Infections in Hospitalized Children - United States, 2018-2024. MMWR Morb Mortal Wkly Rep. 2025;74(23):394-400. https://doi.org/10.15585/mmwr.mm7423a1
  9. Waites KB, Xiao L, Liu Y, Balish MF, Atkinson TP. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev. 2017;30(3):747-809. https://doi.org/10.1128/CMR.00114-16
  10. Wang X, Li M, Luo M, Luo Q, Kang L, Xie H, et al. Mycoplasma pneumoniae triggers pneumonia epidemic in autumn and winter in Beijing: a multicentre, population-based epidemiological study between 2015 and 2020. Emerg Microbes Infect. 2022;11(1):1508-17. https://doi.org/10.1080/22221751.2022.2078228
  11. Biagi C, Cavallo A, Rocca A, Pierantoni L, Antonazzo D, Dondi A, et al. Pulmonary and Extrapulmonary Manifestations in Hospitalized Children with Mycoplasma Pneumoniae Infection. Microorganisms. 2021;9(12):2553. https://doi.org/10.3390/microorganisms9122553
  12. Narita M. Classification of Extrapulmonary Manifestations Due to Mycoplasma pneumoniae Infection on the Basis of Possible Pathogenesis. Front Microbiol. 2016 28;7. https://doi.org/10.3389/fmicb.2016.00023
  13. Wang Z, Peng Y, Yang S, Chen Z, Wang H, Li H, et al. Risk factors for complications of Mycoplasma pneumoniae pneumonia in hospitalized children in China: a systematic review and meta-analysis. BMC Pediatr. 2024;24(1):810. https://doi.org/10.1186/s12887-024-05279-9
  14. Dungu KHS, Holm M, Hartling U, Jensen LH, Nielsen AB, Schmidt LS, et al. Mycoplasma pneumoniae incidence, phenotype, and severity in children and adolescents in Denmark before, during, and after the COVID-19 pandemic: a nationwide multicentre population-based cohort study. The Lancet Regional Health - Europe. 2024;47:101103. https://doi.org/10.1016/j.lanepe.2024.101103
  15. Chen YC, Hsu WY, Chang TH. Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia. Emerg Infect Dis. 2020;26(7):1382-91. https://doi.org/10.3201/eid2607.200017
  16. Mijović B, Aćimović J, Đaković Dević J, Kralj J, Lučić Samardžija V, Djermanović M, et al. Knowledge, Attitudes and Practices of Parents and Pediatricians Regarding Antibiotic Use among Children: Differences in Relation to the Level of Education of the Parents in the Republic of Srpska Bosnia and Herzegovina. Antibiotics. 2022;11(10):1325. https://doi.org/10.3390/antibiotics11101325
  17. Gu Y, Do AD, Fujitomo Y, Ohtake F. Specialty and age-based differences in awareness and attitudes towards antibiotic stewardship: a cross-sectional online survey on Japanese clinic physicians. BMC Infect Dis. 2025;25(1):1186. https://doi.org/10.1186/s12879-025-11583-1
  18. Makević Đurić M, Đurić M. Infekcija Mycoplasma Pneumoniae Kod Dece: Šta Treba Da Znamo? Prev Ped. 2025;11(1−2): 28−32. https://doi.org/10.46793/PP250126008M
  19. Wang Y, Jiao L, Ma L, Xu Z, Liang Y. Pediatric Mycoplasma pneumoniae-induced rash and mucositis in China: clinical spectrum, co-infections and risk factors for recurrence-a retrospective cohort study. Frontiers in Allergy. Allergy 2025;6:1646688. https://doi.org/10.3389/falgy.2025.1646688
  20. O’Neil KM, Addrizzo-Harris DJ. Continuing Medical Education Effect on Physician Knowledge Application and Psychomotor Skills. Chest. 2009;135(3):37S-41S. https://doi.org/10.1378/chest.08-2516

Copyright and license

Copyright © 2026 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Demirci B, Özkaya-Parlakay A, Günaydın D, Efeoğlu-Gülsoy G, Yücel SP. Pediatricians’ knowledge of pediatric Mycoplasma pneumoniae infection in the post–COVID-19 period: A single-center cross-sectional survey from Türkiye. Turk J Pediatr Dis. 2026;Early View:1-5. https://doi.org/10.12956/TJPD.2026.1362